KPTI - Karyopharm Therapeutics EPS misses by $0.01 beats on revenue

Karyopharm Therapeutics (NASDAQ:KPTI): Q3 GAAP EPS of -$0.69 misses by $0.01. Revenue of $37.69M (+76.7% Y/Y) beats by $11.4M. Shares +0.52% PM. Press Release 2021 Outlook: Non-GAAP R&D and SG&A expenses, excluding stock-based compensation expense, are expected to be in the range of $270 million to $290 million. Karyopharm has not reconciled the full year 2021 outlook for non-GAAP R&D and SG&A expenses to full year 2021 outlook for GAAP R&D and SG&A expenses because Karyopharm cannot reliably predict without unreasonable efforts the timing or amount of the factors that substantially contribute to the projection of stock compensation expense, which is excluded from the full year 2021 outlook for non-GAAP R&D and SG&A expenses. The Company expects that its existing cash, cash equivalents and investments, together with growing XPOVIO sales and revenues from existing collaborators, provide it with a cash runway that extends into mid-2023.

For further details see:

Karyopharm Therapeutics EPS misses by $0.01, beats on revenue